Neuroscience

#Drug discovery #Events #Neuroscience #Webinar

Webinar: Where is the innovation in neuroscience drug discovery?

Hosted by Drug Discovery World and sponsored by Emulate, this free webinar explores where innovation is taking place within neuroscience drug discovery.  The webinar sees experts and leaders from the neuroscience sector discuss where innovation is occurring and what the challenges are to overcome for drug… Read More

Webinar date:
Sponsored by Emulate
#News

#Drug discovery #Events #Neuroscience

Where is the innovation in neuroscience drug discovery?

This free webinar, hosted by DDW and sponsored by Emulate, sees experts and thought leaders from the neuroscience sector discuss where innovation is occurring and what the challenges are to overcome for drug discovery projects targeting neuroscience. You will learn: The challenges and opportunities in neuroscience drug discovery & development… Read More

Webinar date:
Sponsored by Emulate
#Webinars

Parkinson's disease
#Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Research reveals “compelling” new drug target for Parkinson’s

Researchers have identified a key enzyme driving forms of Parkinson’s, offering a promising new drug target for the condition.  In Parkinson’s, a protein known as alpha-synuclein builds up in clumps called Lewy bodies in nerve cells in the brain. These clumps of protein stop these cells from… Read More

#Editor's Choice #News

Gold compound
#Alzheimer's #BioInnovation Institute #Biotech hubs #Cognition Therapeutics #India #Interview #Market reporting #Neurodegenerative disorders #Neuroscience #Pregnancy #Start-ups #Women's health

Podcast: Where are scientists making waves in drug discovery?

This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting… Read More

#News

Lecanemab
#Alzheimer's #Biogen #Eisai #European Commission #Monoclonal antibodies #Neuroscience

Lecanemab gets EU approval in early Alzheimer’s

The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for the treatment of adult patients… Read More

#News #Regulatory #Trending News

Patient holding pill in hand
#Alzheimer's #Neuroscience #Phase III trial #Tau protein #TauRx Pharmaceutics

Oral treatment could slow progress of Alzheimer’s disease

Researchers have reported a potential oral treatment for Alzheimer’s disease (AD) that slowed its progression over a period of at least 18 months.  Developed by Singaporean company TauRx Pharmaceutics, the scientists based in Aberdeen, UK, report that hydromethylthionine mesylate (HMTM) could be the first oral treatment for… Read More

#News

Mental health concept
#Antidepressants #Gut-brain interaction #Mental health #Neuroscience

A promising new target for mental health

DDW Editor Reece Armstrong speaks to Kara Margolis, MD, Director of the NYU Pain Research Center and Associate Professor at NYU College of Dentistry and NYU Grossman School of Medicine, and Mark Ansorge, Associate Professor of clinical neurobiology at Columbia University about recent research highlighting the importance between the gut… Read More

#Exclusive Content

Alpha-synuclein protein aggregate
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #Phase II trial

Immunotherapy for Parkinson’s induces positive responses

AC Immune has announced additional interim safety and positive immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056, its anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease (PD).  Dr Andrea Pfeifer, CEO of AC Immune, commented: “We continue to be encouraged by the data… Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Antibody #Gene therapy #Neuroscience #Tau protein #Voyager Therapeutics

Anti-tau antibody and gene therapy show potential in Alzheimer’s

A single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in preclinical studies.  Voyager Therapeutics will share the new data from its two preclinical programmes for Alzheimer’s disease (AD) at the 2025 International… Read More

#News

Hormones in the brain concept
#European Commission #Lundbeck #Neuroscience #Otsuka #Schizophrenia

Brexpiprazole’s EU approval extended to include adolescents

The European Commission (EC) has approved Otsuka’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.  The drug was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.  The EC based its approval on a six-week trial of 316… Read More

#News #Regulatory

Neuroscience
#Neurodegenerative disorders #Neuroscience #Protein degradation #Start-ups #TRIMTECH Therapeutics

Start-up harnesses protein degradation for neurodegeneration

TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, has closed a $31 million seed funding round.   The investment will support further development of the company’s pipeline of central nervous system (CNS) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs.  … Read More

#Business & Investment #News #Start-up Zone

#Gender #Neuroscience #Precision medicine #Women’s Brain Foundation

The urgent need for sex and gender to be recognised in drug discovery

DDW Editor Reece Armstrong speaks to Dr Antonella Santuccione Chadha, CEO of the Women’s Brain Foundation (WBF) about the importance of sex and gender differences in drug discovery efforts. The topic of gender disparity is a prevailing issue in modern society and is something which has caused fierce debate across political… Read More

#Exclusive Content

Genetic engineering concept
#AskBio #FDA #Gene therapy #Neuroscience #Parkinson's

Further FDA support for Parkinson’s gene therapy

AskBio’s investigational gene therapy AB-1005 for the treatment of Parkinson’s disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA).  The FDA decision follows a review of information and data provided by AskBio, including clinical evidence from the open label Phase… Read More

#News #Regulatory

#2025 predictions #Drug discovery #Neuroscience

Neuroscience: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, this was with a focus on technology, machine learning (ML) and artificial intelligence (AI). Here, looking at the neuroscience sector. At the Society for Neuroscience’s annual meeting, Neuroscience 2024, both the turnout and… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

Map of Iceland
#Alzheimer's #Arctic Therapeutics #Dementia #Dermatology #Financing #Neuroscience

Scale-up explores anti-amyloid treatments for dementia

Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a €26.5 million oversubscribed Series A financing from a syndicate of international investors.  The syndicate includes the EIC Fund, Iceland's largest privately-held investment firm Kaldbakur, Investcorp-backed Sanos Group, Swiss-based Cerebrum DAO, The Lurie Family Foundation,… Read More

#Business & Investment #News

#Autism #Fast Track designation #FDA #Neuroscience #Spinogenix

FDA fast-tracks drug for autism cause Fragile X syndrome

The US Food and Drug Administration (FDA) has granted Fast Track designation to SPG601 for the treatment of people with Fragile X syndrome (FXS).  FXS, a known cause of autism, is the leading inherited form of intellectual disability that can produce a wide range of disabling symptoms, with many individuals… Read More

#News #Regulatory